Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
- New Drug Application for CONTEPO ™ submitted to FDA in October 2018 - - Company preparing for potential commercialization of two, first-in-class antibiotics, Lefamulin (IV and Oral) and CONTEPO (IV) in the United States in 2019 - DUBLIN, Ireland , Nov.
View HTML
Toggle Summary Nabriva Therapeutics Completes Submission of New Drug Application to U.S. Food and Drug Administration for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections
DUBLIN, Ireland , Nov. 01, 2018 (GLOBE NEWSWIRE) --   Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced it has submitted a New Drug Application (NDA)
View HTML
Toggle Summary Nabriva Therapeutics to Present Data at ID Week Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO™ (fosfomycin for injection) to Treat Complicated Urinary Tract Infections (cUTIs)
New data continue to support lefamulin and CONTEPO as potential first-in-class antibiotics in the United States that target the most common causative pathogens of CABP and cUTI, including multi-drug resistant (MDR) strains DUBLIN, Ireland , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics
View HTML
Toggle Summary Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, today announced that Ted Schroeder ,
View HTML
Toggle Summary Nabriva Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
- Company preparing for potential commercialization of two first-in-class antibiotics, Lefamulin (IV and Oral) and CONTEPO (IV) in the United States in 2019 - - New Drug Application submissions expected in Q4 2018 - DUBLIN, Ireland , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc
View HTML
Toggle Summary Nabriva Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, today announced that Ted
View HTML
Toggle Summary Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $50 Million
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , July 26, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced the pricing of its underwritten public offering of 18,181,818 ordinary shares at a public offering price of $2.75 per share.
View HTML
Toggle Summary Nabriva Therapeutics Announces Proposed Public Offering of Ordinary Shares
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , July 25, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced that it has commenced an underwritten public offering of $50.0 million of ordinary shares. In addition, Nabriva Therapeutics expects to grant the underwriters an
View HTML
Toggle Summary Nabriva Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland and KING OF PRUSSIA, Pa. and SAN DIEGO , July 25, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, today announced that
View HTML
Toggle Summary Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante Therapeutics
- Acquisition adds Zavante’s CONTEPO ™ , potential first-in-class in the United States injectable antibiotic for cUTIs, to Nabriva’s late-stage anti-infective portfolio - - Nabriva on track to file New Drug Applications for lefamulin and CONTEPO in the fourth quarter of 2018 - - Ted Schroeder
View HTML

For Media Inquiries

PR@nabriva.com


For Investor Relations

David Garrett
Vice President, Corporate Controller and Head of Investor Relations
Nabriva Therapeutics plc

E-mail: david.garrett@nabriva.com